Tuesday, January 10, 2017

Allianz Euroland Equity Growth retains the note ” Silver “. – Invest

Matthias Born manages this fund (ISIN: LU0256840447) since October 2009, in collaboration with Thorsten Winkelmann and co-manager Andreas Hildebrand. Born began his career at Allianz Global Investors in 2001 within the team of Frank Hansen, a manager highly experienced in the segment of small-cap stocks in europe. Since 2007, Born is responsible for the equity fund, the German Concentra, noted ” Silver “, on which he delivered excellent results. The managers are supported by the three other members of the team dedicated to european action for growth.

The investment approach has been put in place by the managers earlier in 2003. It is based on the selection of securities, and the managers are looking for companies of good quality with a structural growth. It is characterized, for example, by an advantage in terms of costs or technology, an activity on a market that is in high growth or an economic model that is superior to the other. The construction of the portfolio is largely free of the indices, which can result in large differences in terms of sector exposure or geographical location. The performance of the fund may also deviate significantly from the index or the middle of the category according to market conditions.

In total, the results produced by the selection of titles have been convincing since 2003 and since the assumption of office of the managers present, in 2009. Under the direction of Matthias Born, the fund ranks among the best in the category Morningstar Equity eurozone Large-Cap stocks, with volatility and a maximum drawdown lower than the average.

The combination of an investment process that’s proven and a management team of seasoned helps make this fund one of our favorites. This fund domiciled in Luxembourg benefit from a tariff more competitive than its German version, a plus for investors. It remains noted to be ” Silver “.

Mathieu Caquineau, CFA

as a Senior Analyst, Research Asset Management

LikeTweet

No comments:

Post a Comment